Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Rating) – Research analysts at HC Wainwright reduced their Q2 2023 EPS estimates for shares of Actinium Pharmaceuticals in a research note issued to investors on Tuesday, May 16th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings per share of ($0.46) for the quarter, down from their prior estimate of ($0.42). HC Wainwright has a “Buy” rating and a $53.00 price objective on the stock. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q3 2023 earnings at ($0.40) EPS, Q4 2023 earnings at ($0.39) EPS, FY2023 earnings at ($1.68) EPS and FY2024 earnings at ($1.12) EPS.
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) last released its quarterly earnings data on Monday, April 3rd. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01). Actinium Pharmaceuticals had a negative net margin of 2,885.09% and a negative return on equity of 46.38%.
Actinium Pharmaceuticals Stock Performance
ATNM stock opened at $8.37 on Thursday. The business’s 50-day moving average is $10.59 and its two-hundred day moving average is $10.22. The company has a market cap of $215.36 million, a price-to-earnings ratio of -6.15 and a beta of 0.38. Actinium Pharmaceuticals has a fifty-two week low of $4.67 and a fifty-two week high of $15.12.
Institutional Investors Weigh In On Actinium Pharmaceuticals
Several institutional investors have recently modified their holdings of the stock. UBS Group AG grew its stake in Actinium Pharmaceuticals by 76.2% in the fourth quarter. UBS Group AG now owns 3,235 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 1,399 shares during the last quarter. Boothbay Fund Management LLC purchased a new stake in Actinium Pharmaceuticals during the first quarter valued at approximately $96,000. Rockefeller Capital Management L.P. grew its holdings in Actinium Pharmaceuticals by 11.3% in the third quarter. Rockefeller Capital Management L.P. now owns 14,331 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,450 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Actinium Pharmaceuticals during the 1st quarter valued at $118,000. Finally, B. Riley Wealth Advisors Inc. purchased a new position in Actinium Pharmaceuticals during the 1st quarter worth $122,000. 11.23% of the stock is owned by institutional investors.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. It also develops and markets medicines for relapsed or refractory cancer patients. The company was founded in 2000 and is headquartered in New York, NY.
- Get a free copy of the StockNews.com research report on Actinium Pharmaceuticals (ATNM)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.